AssetMark Inc
RARE icon

AssetMark Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

AssetMark Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.3K Hold
1,447
– – ﹤0.01% 1845
2026
Q1 		$30.3K Buy
1,447
+371
+34% +$8.35K ﹤0.01% 1918
2025
Q4 		$24.7K Sell
1,076
-8
-0.7% -$263 ﹤0.01% 1934
2025
Q3 		$32.6K Buy
1,084
+1,024
+1,707% +$30.7K ﹤0.01% 1785
2025
Q2 		$2.18K Buy
60
+54
+900% +$1.95K ﹤0.01% 2403
2025
Q1 		$217 Hold
6
– – ﹤0.01% 2524
2024
Q4 		$252 Buy
+6
New +$298 ﹤0.01% 2459
2022
Q4 		– Sell
-18
Closed -$1K – 1646
2022
Q3 		$1K Sell
18
-4,522
-100% -$232K ﹤0.01% 1473
2022
Q2 		$271K Buy
4,540
+102
+2% +$6.28K ﹤0.01% 705
2022
Q1 		$322K Buy
4,438
+2,354
+113% +$164K ﹤0.01% 681
2021
Q4 		$175K Buy
2,084
+2,005
+2,538% +$163K ﹤0.01% 725
2021
Q3 		$7K Buy
+79
New +$7.14K ﹤0.01% 1098
2020
Q1 		– Sell
-31
Closed -$1K – 1506
2019
Q4 		$1K Hold
31
– – ﹤0.01% 1332
2019
Q3 		$1K Buy
31
+18
+138% +$978 ﹤0.01% 1259
2019
Q2 		$1K Hold
13
– – ﹤0.01% 1263
2019
Q1 		$1K Sell
13
-1
-7% -$57 ﹤0.01% 1270
2018
Q4 		$1K Buy
+14
New +$765 ﹤0.01% 1345
2018
Q1 		– Sell
-12
Closed -$1K – 1865
2017
Q4 		$1K Buy
+12
New +$588 ﹤0.01% 1682
2016
Q1 		– Sell
-5
Closed -$1K – 1363
2015
Q4 		$1K Buy
+5
New +$500 ﹤0.01% 1251

Other funds holding RARE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

AssetMark Inc's RARE Position: Q2 2026 in Review

AssetMark Inc held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 1,447 shares worth $48.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

AssetMark Inc first reported a position in RARE in Q4 2015 and has held it in 19 quarters since. The position peaked at $322K in Q1 2022. 60 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • AssetMark Inc held 1,447 shares of Ultragenyx Pharmaceutical worth $48.3K as of Q2 2026.
  • AssetMark Inc left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1845 holding.
  • AssetMark Inc first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and has held it in 19 quarters since.
  • AssetMark Inc's Ultragenyx Pharmaceutical position peaked at $322K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.